Notice Number: NOT-DA-12-031

Key Dates
Release Date: June 8, 2012

Issued by
National Institutes of Health (NIH)

Purpose

The National Institute on Drug Abuse (NIDA) intends to solicit proposals for preclinical evaluation of test compounds as potential pharmacotherapies for substance abuse.  A solicitation will be released through the Federal Business Opportunities website (URL: https://www.fbo.gov/).  The RFP will be released on or about June 15, 2012 and proposals will be due approximately 45 days thereafter.

Research Initiative Details
NIDA intends to solicit proposals for preclinical evaluation of test compounds as potential pharmacotherapies for substance abuse. To this end, the offeror and technical personnel need to have the capability and experience to conduct experiments evaluating compounds in the mouse locomotor activity, rat drug discrimination, rat conditioned place preference, mouse stress-induced potentiation of conditioned place preference, and rat self-administration paradigms. The offeror and technical staff also need to have experience conducting these types of experiments using cocaine, methamphetamine, nicotine, THC, and hallucinogens. Evidence of experience must be documented through publications using the relevant behavioral models listed above. In addition, the offeror needs to have the dedicated laboratory space, animal care facilities, and equipment required to conduct these behavioral assays. Proprietary compounds will be evaluated using established protocols, and the resulting data will be utilized by the Addiction Treatment Discovery Program of the NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse.

In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that the successful contractor possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances prior to award. All offerors must be in compliance with the NIH guidelines on the care and use of laboratory animals. Offerors should demonstrate the capability to administer and coordinate interrelated tasks in an effective and timely manner.

NIDA anticipates the award of a single fixed-price level of effort contract with option years and option quantities.   RFP No. N01DA-13-8908 will be available electronically on or about June 15, 2012. You can access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov or through the NIDA website at the following address: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of an offer will be contained in or accessible through the RFP package. Responses to the RFP will be due on or about July 30, 2012. NIDA will consider proposals submitted by any responsible offeror. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice. This advertisement does not commit the Government to award a contract.

Inquiries

Please direct all inquiries to:

Lisa Bielen
Contract Specialist
NIDA R&D Contracts Management Branch
Office of Acquisitions, NIDA
National Institutes of Health
6001 Executive Blvd., Room 4211 (MSC 9559)
Bethesda, MD  20892-9559
Phone: 301.443.6677
Lisa.bielen@nih.gov

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
NIH . . . Turning Discovery Into Health Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.